Z Stock Recent News

Type C FDA Meeting Requested, Update Expected by Year-End 2025 SEATTLE , Sept. 8, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has requested a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory strategy aimed at accelerating development of low-dose (Z)-endoxifen for breast cancer risk reduction.

Treasury Secretary Scott Bessent announced Trump may declare a national housing emergency this fall to address affordability issues.

US-based agent network can access Showcase to help sellers increase exposure for faster sales SEATTLE , Aug. 26, 2025 /PRNewswire/ -- Zillow® and Berkshire Hathaway HomeServices today announced an agreement to provide the U.S.-based members of its network with access to Zillow Showcase, Zillow's AI-powered premium listing experience. This new agreement follows an initial product partnership with HomeServices of America, Berkshire Hathaway HomeServices' parent company.

Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025 Topline results anticipated in 2026  Positions Atossa for transition into registrational Phase 3 development SEATTLE , Aug. 20, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, announced today it has selected PSI, a leading global contract research organization (CRO), to operationalize and manage its planned (Z)-endoxifen monotherapy dose-ranging study in women with metastatic breast cancer (mBC). The study was designed following guidance from the U.S. Food and Drug Administration (FDA) and is intended to directly inform a subsequent Phase 3 trial.

Orphe Divounguy, Zillow senior economist, joins 'Fast Money' to talk what headwinds are still facing the housing market.

Zillow's rentals platform is driving rapid revenue growth, now accounting for a quarter of revenue and accelerating each quarter. The company's Premier Agent and for-sale business are outperforming the real estate industry, positioning Zillow for further upside when the market rebounds. Zillow's capital-light, high-margin model and expanding after-market services support strong profitability and scalability.

Downgrade Zillow Group to Hold as macro headwinds and slowing mortgage growth introduce near-term uncertainty despite solid execution and share gains. Rentals and Enhanced Markets segments are outperforming, with Rentals up 36% y/y and Multifamily inventory driving structural growth in the business. Mortgage segment's growth is decelerating, raising concerns about the sustainability of Zillow's 'housing super app' strategy and consolidated revenue momentum.

First, it's hard to get too negative when capital expenditures for companies building out AI infrastructure are running near $400 billion annualized, growing roughly 50% Y/Y. These are not small numbers and they've already influenced economic activity across sectors.

Z's Q2 revenues jump 14.5% to beat estimates, but EPS misses the same as rising costs pressure margins despite strong rental growth.

Zillow Group, Inc. (NASDAQ:Z ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Bradley Allen Berning - Vice President of Investor Relations Jeremy Hofmann - Chief Financial Officer Jeremy Wacksman - CEO & Director Conference Call Participants Andrew M. Boone - Citizens JMP Securities, LLC, Research Division Bradley D.